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Infections caused by the ﬁlamentous fungus Aspergillus fumigatus are a signiﬁcant clinical
issue and represent the second most-common form of fungal infection. Azole drugs are
effective against this pathogen but resistant isolates are being found more frequently.
Infections associated with azole resistant A. fumigatus have a signiﬁcantly increased
mortality making understanding drug resistance in this organism a priority. The target of
azole drugs is the lanosterol α-14 demethylase enzyme encoded by the cyp51A gene in A.
fumigatus. Mutations in cyp51A have been described that give rise to azole resistance and
been argued to be the primary, if not sole, contributor to azole resistance. Here, I discuss
recent developments that indicate multiple mechanisms, including increased expression
of ATP-binding cassette (ABC) transporter proteins, contribute to azole resistance. ABC
transporters arewell-established determinants of drug resistance in other fungal pathogens
and seem likely to play a similar role in A. fumigatus.
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INTRODUCTION
Antibiotics have been one of medical science’s greatest advances
but their continued efﬁcacy is at risk. Over prescription
and improper use has led to dramatic increases in resistant
microorganisms with accompanying increased mortality. The
problem of increased resistance is especially acute for fungal
pathogens as the basic eukaryotic cell biology of these organ-
isms limits the classes of antibiotics that avoid effects on the
host.
Aspergillus fumigatus is the primary ﬁlamentous fungal
pathogen of humans and an especially serious issue in any
immunocompromised situation (Ruping et al., 2008). Azole drugs
are most commonly deployed against A. fumigatus (and most
fungi) as these drugs are well-tolerated and can be orally deliv-
ered. The success of azole antifungal therapy has naturally led to
their extensive use both in the clinical setting and agriculturally,
especially in Europe (discussed in Verweij et al., 2009). Strikingly,
azole antifungals have been much more limited in their applica-
tion in theUnited States (Pham et al., 2014) and this seems likely to
help explain the differences between resistance mechanisms seen
in these two regions. Increased azole resistance is a serious issue in
treatment of aspergillosis. Mortality of azole-resistant aspergillosis
can approach 90% (van der Linden et al., 2011).
Although the ﬁrst azole resistant isolates of A. fumigatus were
reported in the United States (Denning et al., 1997), understand-
ing of the molecular basis of resistance was led by experiments
from Europe. Early work on azole resistant isolates of A. fumiga-
tus determined that these organisms contained mutations in one
of the two genes (cyp51A/B) encoding the azole target enzyme:
lanosterol 14α demethylase (Mellado et al., 2001). Focus on this
gene (cyp51A) led to the surprising ﬁnding that the overwhelming
majority of azole resistant strains contained two mutations and
that both alterations were required for azole resistance (Verweij
et al., 2007). This allele is referred to as TR34/L98H and con-
sists of a 34 bp duplication in the promoter region linked to a
replacement of leucine 98 with a histidine residue in the sequence
of the enzyme (Mellado et al., 2007). This cyp51A allele confers
multiazole resistance and has been found in resistant organisms
ranging from Europe to India (Snelders et al., 2008; Chowdhary
et al., 2012).
The origin of the TR34/L98H resistance allele as an environ-
mentally selected variant is supported by several circumstantial
lines of evidence. First, isolates from the soil led to the alarm-
ing discovery that 5–7% of these A. fumigatus strains contain
this multiazole resistance lesion (reviewed in Chowdhary et al.,
2013). Second, patients not previously exposed to azole drugs
also exhibit aspergillosis with the TR34/L98H-containing fun-
gus (Mellado et al., 2007). Third, genomic analyses of multiazole
resistant A. fumigatus determined that strains containing the
TR34/L98H allele were the most closely related compared to other
azole-susceptible organisms, consistent with these drug resistant
strains emerging from a single and recent alteration (Camps et al.,
2012b). Finally, study of azole resistant organisms in the United
States, where agricultural use of azoles is dramatically lower, has
not uncovered the prevalence of the TR34/L98H cyp51A variant
in drug resistant isolates (Pham et al., 2014).
While there is no question cyp51A mutations are important
contributors to azole resistance, more recent studies have pro-
vided evidence that other resistance mechanisms are also at work
in A. fumigatus (reviewed in Vermeulen et al., 2013). These other
mechanisms have been observed in isolates derived from patients
chronically exposed to azole drugs. This long term challenge with
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azole drugs drives generation of mutant spores that are now drug
resistant. Since A. fumigatus exists in a multicellular state, acquisi-
tion of a mutant allele in one nucleus is very unlikely to produce
a resistant organism. However, if a mutant spore is generated,
then a resistant isolate will be produced. Analyses of these mutant
strains of A. fumigatus that have been recovered after azole expo-
sure have uncovered multiple new mechanisms of resistance to
these antifungal drugs. Here I will review recent experiments
that implicate the participation of ATP-binding cassette (ABC)
transporter proteins and other mechanisms in azole resistance of
clinical isolates.
ABC TRANSPORTERS AND DRUG RESISTANCE IN
PATHOGENIC FUNGI
The predominance of the TR34 L98H cyp51A allele inA. fumigatus
represents anuncommongenetic distributionof azole resistance in
other, better understood fungi. The pathogenic fungus for which
we have themost detailed understanding of azole resistancemech-
anisms is the major human pathogen Candida albicans. Extensive
analyses of the molecular basis for azole resistance in C. albi-
cans led to the discovery of at least two different routes. The
C. albicans ERG11 gene encodes the lanosterol 14α demethylase
in this fungus. Changes both in the sequence of the protein as
well as alterations that increase ERG11 transcription are associ-
ated with azole resistance (Perea et al., 2001; Morio et al., 2010).
Increased expression of membrane transporter proteins is a sec-
ond mechanism that synergizes with ERG11 changes (reviewed
in Morschhauser, 2010). Experiments in different clinical isolates
(Selmecki et al., 2008; MacCallum et al., 2010) led to the ﬁnding
that high level azole resistance required the cooperation of both
the ERG11 gene and a transcription factor encoded by the TAC1
gene. The key role of Tac1 is to induce expression of ABC trans-
porter proteins encoded by theCDR1 gene alongwith other targets
(Coste et al., 2004). These transporter proteins are of two differ-
ent functional classes: the ABC transporters and major facilitator
superfamily (MFS) transporters (reviewed in Prasad and Goffeau,
2012; Costa et al., 2014). Typically, these membrane proteins are
found in the plasma membrane (PM) where they are thought to
act as energy-dependent drug efﬂux pumps (Marger and Saier,
1993). Overproduction of the membrane transporters is usually
due to amino acid substitutions in transcription factors that ulti-
mately drive elevated mRNA level corresponding to these drug
pumps.
This theme of elevated ABC transporter expression cooperat-
ing with Erg11 to confer azole resistance is seen in other pathogens
including Candida krusei (Lamping et al., 2009) and Candida
glabrata (Samaranayake et al., 2013). As is usual in instances of
drug resistance, these multiple different mechanisms are engaged
that work together to produce the full in vivo response to drug
challenge. While the synergy of Erg11 and ABC transporters
is well-described in Candida species, evidence implicating ABC
transporters and other proteins in A. fumigatus has been less well-
appreciated, likely owing in part to the elegant demonstrations
tying cyp51A mutations to clinical azole resistance (Snelders et al.,
2008). Recent experiments provide a rationale for reconsidering
the importance of mechanisms beyond cyp51A in azole resistance
in A. fumigatus.
AZOLE RESISTANCE IN A. fumigatus MAY UTILIZE
NON-cyp51A-DEPENDENT MECHANISMS
As discussed above, the large environmental reservoir of
cyp51A azole resistant organisms has focused much attention
on changes in this key target gene giving rise to drug resis-
tant isolates (Verweij et al., 2009). Analyses of A. fumigatus
azole resistant isolates from patient populations undergoing
chronic azole exposure have provided important new informa-
tion implicating other resistance pathways in antifungal resistance
(Figure 1).
The ﬁrst detailed study of azole resistant A. fumigatus strains
that also contained wild-type cyp51A genes came from analyses of
fungal isolates submitted to a regional mycology center at Manch-
ester Hospital in the UK (Howard et al., 2009; Bueid et al., 2010).
These investigators discovered that, between the years of 2004–
2009, azole resistant isolates increased from 5 to 20%. While
another center reported a similar increase in azole resistant A.
fumigatus isolates (Mortensen et al., 2011), the unique feature of
the Manchester data was the presence of a wild-type cyp51A gene
in 43%of these resistant strains. These ﬁndings are consistent with
more recent data from the United States in which a broad survey
of A. fumigatus isolates found an overall lower frequency of azole
resistance (5%) but 98% of these resistant isolates had no cyp51A
lesion known to be associated with azole resistance (Pham et al.,
2014). The origin of the A. fumigatus isolates in the UK and US
studies were very different with the Manchester patients corre-
sponding to patients with chronic aspergillosis and the US isolates
coming from a wide range of sources (Pham et al., 2014). The
primary commonality for the resistant isolates from these two dif-
ferent studies was the lack of cyp51A-dependent changes, strongly
indicating the existence of other avenues of azole resistance.
The ﬁrst data implicating ABC transporters in clinically rele-
vant drug resistance has emerged quite recently. Before discussing
these data, I would like to mention the confusing state of cur-
rent nomenclature for ABC transporters in A. fumigatus. There
is no consensus for gene names in this (or really any) family
of protein in Aspergillus and I propose to adopt a system sug-
gested earlier by Kovalchuk and Driessen (2010). This system
employs a Human Genome Organization-approved scheme for
naming ABC transporters based on their structural organiza-
tion. I will use this nomenclature to refer to ABC transporters
from A. fumigatus discussed here and encourage others to do the
same.
A number of laboratories have demonstrated correlation
between increased ABC transporter expression with associated
azole resistance (Tobin et al., 1997; Slaven et al., 2002; Nasci-
mento et al., 2003; da Silva Ferreira et al., 2006) but a functional
link between the mRNA levels of a given ABC transporter and
azole resistance remained elusive. Follow-up work on A. fumiga-
tus isolates with a wild-type cyp51A gene led to the ﬁnding that
mRNA encoding a particularABC transporter was elevated in 8/11
azole resistant strains (Fraczek et al., 2013). This gene, referred to
here as abcG1 (aka cdr1B aka abcB aka AFUA_1G14330) encodes
a homolog of the well-studied ABC transporters Saccharomyces
cerevisiae Pdr5 and theCandida speciesCdr1. Importantly, disrup-
tion of abcG1 from one of the clinical isolates that overproduced
this transcript led to a reduction in itraconazole MIC from >8
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FIGURE 1 | Relationships of azole resistance determinants in
Aspergillus fumigatus. Known or putative transcription regulators are
indicated in light gray as positive regulators of gene expression. The
nuclear genes encoding the lanosterol α-14 demethylase (cyp51A), a
plasma membrane (PM) ABC transporter (abcG1), or a major
facilitator superfamily (MFS) transporter protein are indicated.
Activation of an MFS-encoding gene by Afyap1 is still speculative at
this point but is known to occur in other fungi (Alarco et al., 1997;
Coleman et al., 1997; Rognon et al., 2006). The Cyp51A protein is
docked to the endoplasmic reticulum (ER) by an N-terminal
membrane spanning domain (Monk et al., 2014) while the AbcG1
protein is localized to the PM.
to 2 mg/L, demonstrating the functional requirement for this in
itraconazole resistance (Fraczek et al., 2013).
Along with this work in clinical isolates, loss of abcG1
was demonstrated to cause profound azole hypersensitivity in
four different laboratory strains (Fraczek et al., 2013; Paul et al.,
2013). Overproduction of the abcG4 (aka cdr1A aka abcA aka
AFUA_2G15130) gene product, that shares the highest degree
of sequence conservation to abcG1, also elevated azole resis-
tance. Fusions of green ﬂuorescent protein to the C-terminus of
either abcG1 or abcG4 indicated that the resulting fusion pro-
teins were localized to the PM, consistent with their activity as
ATP-dependent drug efﬂux pumps (Paul et al., 2013). While func-
tional data implicating both of these ABC transporter proteins
has been provided, these types of demonstrations remained to
be accomplished for the large number (15) of A. fumigatus ABC
transporters in theABCG class of transporter proteins (Kovalchuk
and Driessen, 2010).
While data are accumulating for the role of ABC transporters
in azole resistance in A. fumigatus, other organisms also exhibit
drug resistance that is triggered by changes in transcriptional reg-
ulators (recently reviewed in Paul and Moye-Rowley, 2014). As
mentioned above, C. albicans Tac1 can acquire gain-of-function
mutations that lead to enhanced activation of genes under its con-
trol (Coste et al., 2004). These target genes include the important
azole resistance determinant CDR1. The work of Fraczek et al.
(2013) suggests that similar mutations may be present in A. fumi-
gatus azole resistant isolates overproducing abcG1but these remain
to be found.
However, at least three examples of transcription factors that
are important in azole resistance have been described. The ﬁrst
is the sterol response element binding protein (SREBP) from A.
fumigatus referred to as SrbA (Willger et al., 2008). This regulator
was discovered via its sequence conservation with SREBP from
Schizosaccharomyces pombe and mammals (reviewed in Bien and
Espenshade, 2010). Disruption of the srbA gene led to pronounced
azole hypersensitivity, and perhapsmost interesting, increased ﬂu-
conazole susceptibility. This seems likely to be due to the decreased
expression of cyp51A in the absence of SrbA (Willger et al., 2008)
as cyp51A strains exhibit a similar increased ﬂuconazole suscep-
tibility (Mellado et al., 2005). The importance of the trans-acting
factor SrbA in expression of cyp51A suggests the possibility that
mutants that increase SrbA activity might elevate azole resistance
via their effect on a wild-type cyp51A locus. These type of mutant
alleles of srbA have not been described at present.
A recently discovered azole resistance mechanism involving a
transcription factor was described in an isolate from an immun-
odeﬁcient patient undergoing chronic pulmonary aspergillosis
(Camps et al., 2012a). Isolates recovered from early in the infection
exhibited an azole susceptible phenotype that ultimately transi-
tioned to azole resistant in time. Clever genetic analyses coupled
withwhole genome sequencing approaches detected a substitution
mutation in the hapE gene as being responsible for the increased
azole resistance. A. fumigatus hapE encodes a DNA-binding sub-
unit of the Hap-complex that is a relative of the mammalian
CCAAT-binding protein (see Dolﬁni et al., 2012 for a review).
While a mechanistic explanation of the increased azole resistance
driven by the mutant HapE-containing complex is still unknown,
a potential contributor to this effect is provided by the ﬁnding
that cyp51A expression is elevated in isolates bearing this lesion
(Camps et al., 2012a).
A common link between resistance supported by changes in
SrbA or HapE is the potential involvement of cyp51A. Azole
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resistant mutants with changes in these transcription factors
could still possess a wild-type cyp51A allele yet exhibit elevated
drug resistance. A ﬁnal example that seems likely to be inde-
pendent of cyp51A function is provided by the A. fumigatus
homolog of S. cerevisiae Yap1. This protein is referred to as
Afyap1 and is a basic region-leucine zipper transcription fac-
tor. ScYap1 is regulated by oxidative stress and normally resides
in the cytoplasm due to rapid nuclear export (Kuge et al., 1997;
Yan et al., 1998). Upon oxidative stress, nuclear export of ScYap1
is inhibited and the factor accumulates on target promoters,
resulting in transcriptional induction of genes involved in redox
regulation (reviewed in Morano et al., 2012). Afyap1 has been
demonstrated to be regulated by oxidative stress at the level of
nuclear localization and seems likely to be controlled by oxi-
dants in a manner similar to that seen for ScYap1 (Lessing et al.,
2007).
The relationshipofAfyap1 to azole resistancewasdemonstrated
by work using a truncation form of this protein (Qiao et al., 2010).
The carboxy-terminal cysteine-rich domain (c-CRD) was deleted
from Afyap1 and this mutant protein expressed from a multicopy
plasmid in A. fumigatus. The c-CRD has been extensively studied
in ScYap1 and serves as a negative regulatory site acting to exclude
ScYap1 from the nucleus via interaction with the exportin pro-
tein Crm1 (reviewed in Guttler and Gorlich, 2011). The Afyap1
mutant lacking its c-CRD (referred to as TR Afyap1) was found to
strongly elevate resistance to voriconazole but not inﬂuence itra-
conazole resistance (Qiao et al., 2010). A strain lacking Afyap1 was
unaffected in terms of azole resistance but was highly sensitive to
oxidants.
This behavior of Afyap1 is quite similar to that previously
seen for both the C. albicans Yap1 homolog (Cap1) and ScYap1
(Alarco and Raymond, 1999). Loss of the Yap1-encoding genes
from any of these organisms causes oxidative stress hypersensi-
tivity but has no marked inﬂuence on azole sensitivity (Alarco
et al., 1997; Alarco and Raymond, 1999). However, production of
hypermorphic forms of Yap1 homologs does enhance azole resis-
tance, typically through induction of expression of MFS-encoding
gene expression (Alarco et al., 1997). Strikingly, in S. cerevisiae,
while deletion of the gene encoding the major ABC transporter
involved in azole resistance (Sc PDR5) led to a profound sensitiv-
ity to this drug (Sanglard et al., 1995), overproduction of ScYap1
fully suppressed this drug sensitivity (Alarco et al., 1997). This also
seems likely to occur in A. fumigatus although further work will
be required to conﬁrm this possibility.
SUMMARY
While early analyses of azole resistance in A. fumigatus were con-
sistent with changes in the cyp51A gene being the primary if not
sole driver of drug resistance, recent ﬁndings and a more nuanced
view of resistance mechanisms do not support this simple picture.
The key differentiator between the nearly exclusive involvement
of cyp51A mutants in azole resistance and contribution of other
pathways comes from consideration of the origin of resistant A.
fumigatus isolates. An environmental reservoir of resistant organ-
isms, certainly impacted if not completely driven by extensive use
of azole-based agricultural fungicides, produced a large number
of highly azole resistant isolates that were routinely discovered in
patient populations (Verweij et al., 2009). During screening for
azole resistant A. fumigatus appearing during chronic drug expo-
sure, frequent isolates were found that containedwild-type version
of cyp51A (Bueid et al., 2010). These resistant isolates indicate the
presence of other resistance pathways in this ﬁlamentous fungus
as seen in more extensively studied pathogens like the Candida
species (Morschhauser, 2002).
The involvement of ABC transporters in A. fumigatus is most
clearly indicated by the studies of Fraczek et al. (2013). Overpro-
duction of abcG1was linked tomultiple clinical isolates and shown
to be required for azole resistance in one. The increasing number
of azole tolerant isolates recovered from patients that exhibit no
changes in the cyp51A locus supports the view that other mecha-
nisms, such as ABC transporter overproduction, will be found to
play important roles in azole resistance in A. fumigatus.
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